

Anti-CD20 & CD3 Reference Antibody (Odronextamab)

Catalog # APR11596

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P11836 & P07766
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	CD20,CD3
Expression system	CHO

Protein Information

Images




Anti-CD20 & CD3 Reference Antibody (Odronextamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-CD20 & CD3 Reference Antibody (Odronextamab) is 97.48%, determined by SEC-HPLC.


Odronextamab bound to CD20 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Odronextamab bound human CD20-VLP, and the EC50 was 0.1964 nM.





Odronextamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Odronextamab bound to Raji cells, and the EC50 was 17.3 nM.



Odronextamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Odronextamab bound to huCD3e-jurkat cells, and the EC50 was 26.520 nM.



Co-incubation of Odronextab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Odronextamab was able to activate the NF-AT signaling pathway.



The detected molecular weight of Anti-CD20 & CD3 Reference Antibody (Odronextamab) is 145.34 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.